Perspective Therapeutics
CATXPhase 2Perspective Therapeutics is on a mission to transform cancer treatment with its innovative, image-guided targeted alpha-particle therapy platform. Formed in February 2023 from the merger of Viewpoint Molecular Targeting and Isoray, the company leverages proprietary Pb-212-based radiotherapies and a matched imaging agent (Pb-203) for a precise theranostic approach. Its clinical pipeline includes programs for neuroendocrine tumors (VMT-α-NET), melanoma (VMT01/02), and fibroblast activation protein (PSV359) positive solid tumors, positioning it at the forefront of the next generation of radiopharmaceuticals.
CATX · Stock Price
Historical price data
AI Company Overview
Perspective Therapeutics is on a mission to transform cancer treatment with its innovative, image-guided targeted alpha-particle therapy platform. Formed in February 2023 from the merger of Viewpoint Molecular Targeting and Isoray, the company leverages proprietary Pb-212-based radiotherapies and a matched imaging agent (Pb-203) for a precise theranostic approach. Its clinical pipeline includes programs for neuroendocrine tumors (VMT-α-NET), melanoma (VMT01/02), and fibroblast activation protein (PSV359) positive solid tumors, positioning it at the forefront of the next generation of radiopharmaceuticals.
Technology Platform
A theranostic platform using the chemically matched isotope pair Pb-212 (alpha therapy) and Pb-203 (imaging), conjugated via a proprietary chelator to high-affinity tumor-targeting peptides for precise cancer treatment.
Pipeline Snapshot
66 drugs in pipeline
| Drug | Indication | Stage |
|---|---|---|
| [203Pb]VMT-α-NET + [212Pb]VMT-α-NET | Neuroendocrine Tumors Unresectable | Phase 1/2 |
| [203Pb]VMT01 + [212Pb]VMT01 + Nivolumab | Recurrent Melanoma (Skin) | Phase 1/2 |
| [203Pb]Pb-PSV359 + [212Pb]Pb-PSV359 | Pancreatic Ductal Adenocarcinoma | Phase 1/2 |
| [203Pb]VMT-α-NET | Neuroendocrine Tumor Grade 2 | Phase 1 |
| [212Pb] VMT-α-NET | Neuroendocrine Tumors | Phase 1 |
Funding History
3Total raised: $77M
Opportunities
Risk Factors
Competitive Landscape
Competes with other targeted alpha therapy developers like Bayer, RadioMedix/Orano Med, and Actinium Pharmaceuticals, as well as large pharma (Novartis, Pfizer). Differentiation lies in its Pb-212 platform, proprietary chelator/peptides, and integrated theranostic approach with Pb-203 imaging.
Company Info
Trading
Contact
Therapeutic Areas
Claim your profile to update information, add pipeline data, and connect with investors.
Claim profile